PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Texas Instruments Incorporated (TXN)
205.980.01 (0.00%)
205.24 - 207.41
139.95 - 221.69
4.54M / 6.54M (Avg.)
37.59 | 5.48
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
5.62%
Positive revenue growth while AVGO is negative. John Neff might see a notable competitive edge here.
14.26%
Positive gross profit growth while AVGO is negative. John Neff would see a clear operational edge over the competitor.
51.57%
Positive EBIT growth while AVGO is negative. John Neff might see a substantial edge in operational management.
129.37%
Positive operating income growth while AVGO is negative. John Neff might view this as a competitive edge in operations.
82.32%
Positive net income growth while AVGO is negative. John Neff might see a big relative performance advantage.
84.37%
Positive EPS growth while AVGO is negative. John Neff might see a significant comparative advantage in per-share earnings dynamics.
81.25%
Positive diluted EPS growth while AVGO is negative. John Neff might view this as a strong relative advantage in controlling dilution.
-0.36%
Share reduction while AVGO is at 0.00%. Joel Greenblatt would see if the company has a better buyback policy than the competitor.
-0.53%
Reduced diluted shares while AVGO is at 0.00%. Joel Greenblatt would see a relative advantage if the competitor is diluting more.
33.67%
Dividend growth above 1.5x AVGO's 11.90%. David Dodd would verify if the firm's cash flow is robust enough for these payouts.
87.22%
OCF growth above 1.5x AVGO's 3.24%. David Dodd would confirm a clear edge in underlying cash generation.
109.06%
FCF growth above 1.5x AVGO's 22.03%. David Dodd would verify if the firm’s strategic investments yield superior returns.
104.15%
10Y revenue/share CAGR above 1.5x AVGO's 50.43%. David Dodd would confirm if management’s strategic vision consistently outperforms the competitor.
8.82%
5Y revenue/share CAGR under 50% of AVGO's 50.43%. Michael Burry would suspect a significant competitive gap or product weakness.
-4.55%
Negative 3Y CAGR while AVGO stands at 5.58%. Joel Greenblatt would look for missteps or fading competitiveness that hurt sales.
179.43%
10Y OCF/share CAGR 1.25-1.5x AVGO's 151.75%. Bruce Berkowitz would confirm if the firm's long-term capital allocation yields better cash returns.
55.41%
Below 50% of AVGO's 151.75%. Michael Burry would be alarmed about sustained underperformance in generating free operational cash.
31.35%
3Y OCF/share CAGR at 50-75% of AVGO's 60.69%. Martin Whitman would suspect weaker recent execution or product competitiveness.
754.81%
Net income/share CAGR above 1.5x AVGO's 417.10% over 10 years. David Dodd would confirm if brand, IP, or scale secure this persistent advantage.
34.33%
Below 50% of AVGO's 417.10%. Michael Burry would worry about a substantial lag vs. the competitor’s profit ramp-up.
-6.00%
Negative 3Y CAGR while AVGO is 21.47%. Joel Greenblatt might call for a short-term turnaround strategy or cost realignment.
58.52%
Below 50% of AVGO's 199.65%. Michael Burry would suspect poor capital allocation or persistent net losses eroding long-term equity build-up.
32.67%
Below 50% of AVGO's 199.65%. Michael Burry sees a substantially weaker mid-term book value expansion strategy in place.
24.26%
Below 50% of AVGO's 110.51%. Michael Burry suspects a serious short-term disadvantage in building book value.
1208.79%
Dividend/share CAGR of 1208.79% while AVGO is zero. Bruce Berkowitz sees a slight advantage in stepping up payouts steadily.
180.15%
Dividend/share CAGR of 180.15% while AVGO is zero. Bruce Berkowitz sees a minor advantage in stepping up distributions, even modestly.
130.21%
3Y dividend/share CAGR of 130.21% while AVGO is zero. Bruce Berkowitz sees a minor positive difference that could attract dividend-focused investors.
11.85%
AR growth well above AVGO's 1.88%. Michael Burry fears inflated revenue or higher default risk in the near future.
1.18%
Inventory shrinking or stable vs. AVGO's 10.10%. David Dodd confirms the company’s supply-chain is more efficient if sales are unaffected.
-1.54%
Negative asset growth while AVGO invests at 5.08%. Joel Greenblatt checks if the competitor might capture more market share unless our returns remain higher.
1.43%
Under 50% of AVGO's 3.69%. Michael Burry raises concerns about the firm’s ability to build intrinsic value relative to its rival.
-9.11%
We’re deleveraging while AVGO stands at 0.00%. Joel Greenblatt considers if we gain a balance-sheet advantage for potential downturns.
-7.16%
Our R&D shrinks while AVGO invests at 2.15%. Joel Greenblatt checks if we risk falling behind a competitor’s new product pipeline.
2.61%
We expand SG&A while AVGO cuts. John Neff might see the competitor as more cost-optimized unless we expect big payoffs from the overhead growth.